Contraceptive Injection | SINGAPORE SEXUALHEALTH™
Contraceptive Injection | SINGAPORE SEXUALHEALTH™ @singaporesexualhealth_com: Contraceptive injection, Depo-Provera®. Hormonal contraceptive, for birth control and contraception, Singapore. Private & confidential service.
Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
| SHIM CLINIC|
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Contraceptive / Contraception / Birth control methods available are mostly for females, and they include: Contraceptive injection Depo-Provera® is a progestogen-only, depot medroxyprogesterone acetate (DMPA) long acting injectable contraceptive. One dose is given once every three months. (Four times a year)
(of HIV/STD/pregnancy), and what you can do before and after exposure.
MEDROXYPROGESTERONE ACETATE Tablet [A-S Medication Solutions]
Fri, 25 Mar 2016 05:00:00 +0100 | DailyMed Drug Label Updates
Updated Date: Mar 25, 2016 EST (Source: DailyMed Drug Label Updates)
Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia
Fri, 18 Mar 2016 00:00:00 +0100 | Reproductive Sciences
The objective of this study was to assess effectiveness and safety of Depo-Provera (medroxyprogesterone acetate) in treatment of endometrial hyperplasia (EH) and to compare it with norethisterone acetate (NETA) as an oral progestogen treatment. One hundred forty six women aged 35 to 50 years with abnormal uterine bleeding and diagnosed as having EH were randomized to receive either Depo-Provera, one injection every 3 months for 6 months (2 doses), or oral cyclic NETA, 15 mg daily for 14 days per cycle for 6 months. Primary outcome measure was regression of EH. Secondary outcome variables were side effects of treatment, persistence/progression of EH during follow-up period. After 6 months of treatment, Depo-Provera was more successful in achieving regression of nonatypical EH than NETA (67 ...
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP Trial
Thu, 10 Mar 2016 00:00:00 +0100 | Contraception
To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups. (Source: Contraception)
Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial
Tue, 01 Mar 2016 06:00:00 +0100 | Medicine
Abstract: Ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation is a current challenge for patients with polycystic ovarian syndrome (PCOS). Our previous studies indicated that progestin can prevent premature luteinizing hormone (LH) surge or moderate/severe OHSS in the general subfertile population, both in the follicular-phase and luteal-phase ovarian stimulation but it is unclear if this is true for patients with PCOS.
Chronic Pelvic Pain in Women.
Tue, 01 Mar 2016 00:00:00 +0100 | American Family Physician
Authors: Speer LM, Mushkbar S, Erbele T
Tue, 01 Mar 2016 00:00:00 +0100 | Reactions Weekly
(Source: Reactions Weekly)
Activity of binary mixtures of drospirenone with progesterone and 17α-ethinylestradiol in vitro and in vivo
Mon, 29 Feb 2016 00:00:00 +0100 | Aquatic Toxicology
Publication date: May 2016 Source:Aquatic Toxicology, Volume 174 Author(s): Nadine Madeleine Rossier, Geraldine Chew, Kun Zhang, Francesco Riva, Karl Fent Despite potential exposure of aquatic organisms to mixtures of steroid hormones, very little is known on their joint activity in fish. Drospirenone (DRS) is a new synthetic progestin used in contraceptive pills in combination with 17α-ethinylestradiol (EE2). Here we systematically analyzed effects of DRS in binary mixtures with progesterone (P4) and EE2. First, we determined the in vitro activity of single compounds in recombinant yeast assays that express the human progesterone, androgen, or estrogen receptor, followed by determination of mixture activities of DRS and P4, DRS and EE2, as well as medroxyprogesterone acetate (MPA)...
Abstract A11: Cyclin A expression and endocrine resistance in an experimental model of murine mammary carcinomas
Mon, 29 Feb 2016 00:00:00 +0100 | Molecular Cancer Research
Most of human breast cancers are aneuploid because of chromosome missegregation occurring during mitosis. Deregulation in the control of cell cycle progression is frequently found in mammary carcinomas and is associated with mitotic spindle checkpoint defects and aneuploidy. The Laboratory of Hormonal Carcinogenesis has developed an experimental model of mammary carcinomas by the administration of medroxyprogesterone acetate (MPA) to BALB/c mice. These tumors are metastatic luminal ductal carcinomas, which express estrogen and progesterone receptors (PR) and show different responses to antiprogestin treatment. An association between PR isoform expression and endocrine therapy resistance was found in these mammary carcinomas. Tumors with higher levels of isoform A of PR (PRA) than isoform B...
Abstract A43: Context-dependent growth effects of progestins in estrogen receptor-positive breast cancer patient-derived xenografts (PDX)
Mon, 29 Feb 2016 00:00:00 +0100 | Molecular Cancer Research
Conclusion: Progestins have mixed effects on breast cancer PDX tumor growth. Tumors that have high ER and PR and are highly estrogen-dependent are more likely to exhibit strong growth inhibition by progestins (both P4 and MPA). Tumors with mixed luminal/basal phenotype that have less ER and PR and are moderately estrogen-dependent are less likely to be progestin-inhibited. In tumors with low ER and PR but high AR content MPA can act as an AR agonist to stimulate growth. Tumor-specific downstream estrogen-dependent pathways such as Notch may indicate whether progestins are therapeutic. Additional tumors are needed to confirm these results with the long term goal of developing a molecular assay to define those tumors that may benefit from progestin treatment.Citation Format: Jessica Finlay-S...
Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate
Thu, 25 Feb 2016 15:19:42 +0100 | JAIDS Journal of Acquired Immune Deficiency Syndromes
Conclusions: Initiation of DMPA led to sustained shifts in vaginal bacterial concentrations and levels of inflammatory mediators. Further studies are warranted to outline components of the vaginal microbiota influenced by DMPA use and impact on HIV susceptibility. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)